bluebird bio, Inc. (NASDAQ:BLUE) has received a consensus rating of “Hold” from the twenty-three brokerages that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $129.26.

A number of research analysts have recently commented on BLUE shares. Jefferies Group LLC reissued a “buy” rating on shares of bluebird bio in a research report on Thursday, July 6th. Morgan Stanley reissued an “equal weight” rating and set a $103.00 target price (down from $105.00) on shares of bluebird bio in a research report on Monday, July 10th. Zacks Investment Research cut shares of bluebird bio from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Cantor Fitzgerald reissued a “sell” rating and set a $39.00 target price on shares of bluebird bio in a research report on Monday, July 24th. Finally, Sanford C. Bernstein started coverage on shares of bluebird bio in a research report on Thursday, July 27th. They set a “market perform” rating and a $109.00 target price on the stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/02/bluebird-bio-inc-blue-receives-consensus-rating-of-hold-from-analysts.html.

In other news, insider Eric Sullivan sold 861 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $93.83, for a total transaction of $80,787.63. Following the completion of the transaction, the insider now owns 5,924 shares in the company, valued at $555,848.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Nick Leschly sold 46,833 shares of the company’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $122.27, for a total transaction of $5,726,270.91. Following the transaction, the insider now owns 289,368 shares of the company’s stock, valued at approximately $35,381,025.36. The disclosure for this sale can be found here. Insiders have sold 150,002 shares of company stock worth $18,840,335 over the last three months. 3.90% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of bluebird bio by 9.6% during the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after acquiring an additional 587,236 shares during the last quarter. Capital Research Global Investors grew its position in bluebird bio by 9.9% in the 2nd quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after buying an additional 493,072 shares in the last quarter. Baillie Gifford & Co. grew its position in bluebird bio by 3.8% in the 2nd quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock valued at $567,339,000 after buying an additional 196,025 shares in the last quarter. Vanguard Group Inc. grew its position in bluebird bio by 10.7% in the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after buying an additional 343,856 shares in the last quarter. Finally, BlackRock Inc. grew its position in bluebird bio by 4.3% in the 2nd quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after buying an additional 138,141 shares in the last quarter.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. During the same period in the previous year, the firm posted ($2.07) earnings per share. The company’s revenue for the quarter was up 397.4% on a year-over-year basis.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.